click below
click below
Normal Size Small Size show me how
basic drug therapy f
drug therapy final
| Question | Answer |
|---|---|
| agonist | drugs that interact with a receptor to stimulate a predicable response |
| agranulocytosis | abnormal condition of the blood causing severe reduction of the number of granulocytes. |
| carinogenicity | effects of drugs or substances that cause the increase of cancer |
| displacement | one drug takes the place of another drug increasing the activity of the 1st. |
| leukocytosis | excess of white blood cells |
| nephrotoxicity | drug or substance has destructive effect on kidney |
| passive diffusion | movement from higher to lower across a membrane |
| pharmacology | the study of drugs and their interactions in living organisms |
| distribuiton | the transport of drug molecules through the body |
| protein binding | the reaction of a drug with albumin that allows the albumin to release part of the drug dosage and store the other part. |
| thrombocytopenia | abnormal hematologic condition which there are decreased # of platelets |
| tolerence | increasing resistance to the usual effects of an established dosage of a drug as a result of continued use |
| adverse reactions | an action that is different than the planned effect |
| depression | decrease in activity of cells caused by the action of a drug |
| idiosyncratic | abnormal or unusual action of a drug when it is 1st administered, particular to the individual |
| prophylactic | an agent or measure used to prevent disease |
| therapeutic | positive change or desired effect caused by a drug |
| anaphylaxis | an extreme hypersensitivity to a drug and is an emergency situation |
| generic name | the name of a drug that is related to the chemical or official name and is independent of the manufacturer |
| serum albumin | protein in the blood |
| infant absorption | weight is most significantover age. Topical absorption is faster than adult |
| narcotic administration | (blank) |
| Schedule 1 drug | high potential for abuse, illegal |
| schedule 2 drug | high potential for abuse, may lead to severe dependence |
| schedule 3 | may lead to moderate or low dependence |
| schedule 4 | low potential for abuse |
| category A | no risk to fetus in first trimester has been shown |
| category B | no risk has been seen in animals, there is insufficient data regarding pregnant women |
| Category C | adverse effects have been seen in animals but insufficient data in pregnant women |
| category D | human fetal risk has been demonstrated |
| Category X | human fetal risk is clearly documented |
| interference | one drug inhibits the metabolism or exretion of another drug |
| demulence | any of several oily substances used to soothe a body part or decrease inflamation |
| onset | time it takes a drug to elicit a therapeutic response |
| duration | time the drug concentration is sufficient to elicit a therapeutic response |
| peak | time it takes a drug to reach its maximum therapeutic response |
| FDA | food drug administration |
| poly-pharmacy | the use of many different drugs in treating a patient who may have one or several health problems |
| stat | give one time, immediately |
| prn | give as necessary |
| now | give now |
| asap | as soon as possible |
| supplemental therapy | gives the body a substance needed to maintain normal function |
| incompatibility | 2 drugs that when used together cause deterioration of one drug or a drug interaction. |
| antagonist | opposing actions of drugs |
| biotransformation | metabolism |
| chemical mediators | powerful substances liberated during the inflammatory process |
| leukopenia | lack of white blood cells |
| pallative | care of comfort |
| pharmacodynamics | the way the drug works in the tissue at the cell level |
| pharmacokinetics | absorption, distribution, metabolism, excretion |
| absorption | process that occurs between the time a drug enters the body and the time it enters the blood stream |
| excretion | the elimination of a drug from the body |
| teratogenicity | result in structural defects in unborn fetus |
| synergist | the combined effect of two drugs is greater than each drug taken alone. |
| maintenance dose | dose needed to achieve therapuetic level |
| untoward effects | (blank) |
| potentiate | an effect that occurs when a drug increases or prolongs the action of another drug |
| facilitated diffusion | drug molecules are combined with a carrier substance to move across membranes |
| controlled substance | drugs regulated for distribution and catergorized by therapeutic usefulness and potential for abuse |
| cumulative effects | when drugs are not excreted from the body as new drugs are absorbed |
| half-life | the time required for the serum concentration of a drug to decrease by 50% |
| brand name | same as trade name, has the registered trade mark. registered by the manufacturer |
| trade name | the name designated and patented by the manufacturer |
| nursing processs R/T drug admin. | record, report and monitor |
| efficacy | effectiveness of a drug, drugs ability to produce a desired chemical change in the body |
| admin schedules | (blank) |
| negligence | conduct that falls below the established standard of care |
| malpractice | professional misconduct and lack of skill in the performace of a duty or task |
| maintenance therapy | (blank) |
| dependence | a psychological or physilogical need for a drug |
| percutaneous | topical, sublingual, inhale |
| parenteral | IV (the fastest route) IM, SQ |
| enteral | oral (slowest route) nasogastic-,j-tube |
| single | administer at a certain time, only once |
| hypersensitivity/allergic reaction | occurs having been previously exposed to a drug |